编辑精选——肾旁腹主动脉瘤腔内与开放修复术后按年龄分层的中期生存分析
基于血管质量倡议(VQI)2014至2021年数据,比较肾旁腹主动脉瘤行开窗腔内修复(F-EVAR)与复杂开放修复(c-OAR)后的年龄分层死亡结局。共纳入F-EVAR 1961例、c-OAR 3385例,按<65岁、65-75岁、>75岁分层。在≥65岁患者中F-EVAR围术期死亡率低于c-OAR,但5年死亡率各年龄组相似。
要点
- 65-75岁患者F-EVAR围术期死亡率2.2% vs c-OAR 5.0%(HR 0.50,95%CI 0.30-0.79,p=.004)。
- >75岁患者F-EVAR围术期死亡率2.2% vs c-OAR 6.5%(HR 0.26,95%CI 0.13-0.47,p<.001)。
- <65岁患者F-EVAR与c-OAR围术期死亡率无显著差异(0.9% vs 2.1%;HR 0.40,95%CI 0.07-1.44,p=.22)。
核心结论
- 肾旁腹主动脉瘤患者中,≥65岁者F-EVAR围术期死亡率低于c-OAR,<65岁者两者相似。
- 5年死亡率各年龄组F-EVAR与c-OAR相似,但年轻患者中F-EVAR有死亡率较高的非显著趋势。
研究设计与样本
- 回顾性队列研究,纳入血管质量倡议(VQI)2014至2021年首次择期F-EVAR或c-OAR修复肾旁腹主动脉瘤的患者。
- F-EVAR 1961例(82%为商用开窗支架,18%为医师改良移植物),c-OAR 3385例。
- 按年龄分为<65岁、65-75岁、>75岁三组,采用逆概率加权进行风险校正。
主要发现
- 各年龄组中F-EVAR(vs c-OAR)的分布为:<65岁23%,65-75岁33%,>75岁52%。
- <65岁:F-EVAR vs c-OAR围术期死亡率0.9% vs 2.1%(HR 0.40,95%CI 0.07-1.44,p=.22),5年死亡率13% vs 9.5%(HR 1.44,95%CI 0.71-2.90,p=.31),均无显著差异。
- 65-75岁:F-EVAR vs c-OAR围术期死亡率2.2% vs 5.0%(HR 0.50,95%CI 0.30-0.79,p=.004),5年死亡率13% vs 13%(HR 0.94,95%CI 0.65-1.36,p=.74)。
- >75岁:F-EVAR vs c-OAR围术期死亡率2.2% vs 6.5%(HR 0.26,95%CI 0.13-0.47,p<.001),5年死亡率18% vs 21%(HR 0.83,95%CI 0.57-1.20,p=.31)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Age stratified mortality was examined following fenestrated endovascular aneurysm repair (F-EVAR) vs. open repair of juxtarenal abdominal aortic aneurysms (AAAs) METHODS: All patients undergoing first time elective F-EVAR and complex open aneurysm repair (c-OAR) for juxtarenal AAA in the Vascular Quality Initiative between 2014 and 2021 were identified. Open repairs were compared with commercially available fenestrated endovascular aneurysm repair and physician modified endografts (PMEGs). Patients were stratified into three age groups (< 65, 65 - 75, > 75 years). Primary outcomes were peri-operative and five year mortality, and inverse probability weighted risk adjustment was performed to account for baseline differences. RESULTS: Overall, 1 961 patients underwent F-EVAR (82% commercial F-EVAR, 18% PMEG) and 3 385 patients underwent c-OAR. Across age groups, the distribution of F-EVAR (vs. c-OAR) was: < 65 years: 23%, 65 - 75 years: 33%, > 75 years: 52%. After adjustment, among patients < 65 years, compared with c-OAR, F-EVAR was associated with similar peri-operative mortality (0.9% vs. 2.1%; hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.07 - 1.44], p = .22), and five year mortality (13% vs. 9.5%; HR 1.44, 95% CI 0.71 - 2.90, p = .31). Among patients aged 65 - 75 years, between juxtarenal AAA repair modalities, compared with c-OAR, F-EVAR was associated with a significantly lower risk of peri-operative mortality (2.2% vs. 5.0%; HR 0.50, 95% CI 0.30 - 0.79, p = .004), and five year mortality (13% vs. 13%; HR 0.94, 95% CI 0.65 - 1.36, p = .74). Similarly, among patients > 75 years, compared with c-OAR, F-EVAR was associated with lower peri-operative mortality (2.2% vs. 6.5%; HR 0.26, 95% CI 0.13 - 0.47, p < .001), but with similar five year mortality (18% vs. 21%; HR 0.83, 95% CI 0.57 - 1.20, p = .31). CONCLUSION: Among patients with a juxtarenal AAA, F-EVAR was associated with a lower peri-operative mortality compared with c-OAR in patients ≥ 65 years, but was similar in those < 65 years. At five years, F-EVAR was associated with similar mortality in all age groups, though there was a non-significant trend for a higher mortality rate in younger patients.
引用
- Rastogi V, Varkevisser RRB, Patel PB, et al. Editor's Choice -- Age Stratified Midterm Survival Following Endovascular Versus Open Repair of Juxtarenal Abdominal Aortic Aneurysms. Eur J Vasc Endovasc Surg. 2023. PMID: 37586459. doi:10.1016/j.ejvs.2023.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。